|drug2103||Nasal Dexamethasone Wiki||1.00|
|drug1306||Follow-up at 14 days Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This Clinical Trial evaluates nasal administration of Dexamethasone as an adjuvant treatment strategy for non-critically ill hospitalized participants with SARS CoV-2 infection.
Description: Evaluation of the clinical status of patients after randomization, defined as a two point improvement in the WHO 7-point Ordinal ScaleMeasure: Time of clinical improvement Time: 10 days after randomization
Description: All-cause mortality rates at 28 days after randomizationMeasure: Time-to-death from all causes Time: 28 days after randomization
Description: Ventilator-free days, defined as alive and not requiring mechanical ventilation, at 10 days after randomization.Measure: Time free from mechanical ventilation Time: 10 days after randomization
Description: Virological measurements, including proportions with detection of viral RNA over time and measurements of viral RNA titer area under the curve (AUC).Measure: Viral load Time: 10 days after randomization
Description: Length of hospital stay in daysMeasure: Length of hospital stay Time: 10 days after randomization
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports